tRNA衍生的小RNA(tsRNA)以核酸酶依赖性方式产生,以响应癌症中常见的多种应激。我们专注于富含癌症的tsRNA签名,以开发基于唾液外泌体的人类食管鳞状细胞癌(ESCC)的非侵入性生物标志物。
在一项初步研究中,通过从ESCC患者(n=3)和健康对照(n=3)获得的唾液外泌体的RNA测序鉴定了富含癌症的小RNA,并在发现队列(n=66)中进一步验证。使用新开发的生物标志物特征,在两个ESCC高发病率区域(分别为320和200)进行了多中心前瞻性观察研究。
tsRNA(tRNA-GlyGCC-5)和以前未被证明的小RNA在ESCC患者的唾液外泌体中被特异性富集,ESCC组织和ESCC细胞。由这些小RNA组成的双标记能够以高灵敏度(90.50%)和特异性(94.20%)将ESCC患者与对照区分开。基于双签名预后风险评分(RSP),与低RSP患者相比,高RSP患者的总生存期(OS)(HR4.95,95CI2.90-8.46)和无进展生存期(PFS)(HR3.69,95CI2.24-6.10)均较短.此外,辅助治疗仅对RSP高而非低的患者改善OS(HR0.47,95CI0.29-0.77)和PFS(HR0.36,95CI0.21-0.62).这些发现在训练和验证队列中都是一致的。
基于tsRNA的特征不仅具有诊断和预后的潜力,而且还可以作为术前生物标志物来选择将从辅助治疗中受益的患者。
食管鳞状细胞癌诊断生物标志物的前瞻性研究,ChiCTR2000031507。2016年4月3日注册-回顾性注册。
The tRNA-derived small RNAs (tsRNAs) are produced in a nuclease-dependent manner in responses to variety of stresses that are common in cancers. We focus on a cancer-enriched tsRNA signature to develop a salivary exosome-based non-invasive biomarker for human esophageal squamous cell carcinoma (ESCC).
Cancer-enriched small RNAs were identified by RNA sequencing of salivary exosomes obtained from ESCC patients (n = 3) and healthy controls (n = 3) in a pilot
study and further validated in discovery cohort (n = 66). A multicenter prospective observational
study was conducted in two ESCC high-incidence regions (n = 320 and 200, respectively) using the newly developed biomarker signature.
The tsRNA (tRNA-GlyGCC-5) and a previously undocumented small RNA were specifically enriched in salivary exosomes of ESCC patients, ESCC tissues and ESCC cells. The bi-signature composed of these small RNAs was able to discriminate ESCC patients from the controls with high sensitivity (90.50%) and specificity (94.20%). Based on the bi-signature Risk Score for Prognosis (RSP), patients with high-RSP have both shorter overall survival (OS) (HR 4.95, 95%CI 2.90-8.46) and progression-free survival (PFS) (HR 3.69, 95%CI 2.24-6.10) than those with low-RSP. In addition, adjuvant therapy improved OS (HR 0.47, 95%CI 0.29-0.77) and PFS (HR 0.36, 95%CI 0.21-0.62) only for patients with high but not low RSP. These findings are consistent in both training and validation cohort.
The tsRNA-based signature not only has the potential for diagnosis and prognosis but also may serve as a pre-operative biomarker to select patients who would benefit from adjuvant therapy.
A prospective
study of diagnosis biomarkers of esophageal squamous cell carcinoma, ChiCTR2000031507 . Registered 3 April 2016 - Retrospectively registered.